| ||||||||||||||
|
|
|||||||||||||



*Visceral Physiology Institute and Departments of
Anaesthetics and
Obstetrics and Gynaecology, Groote Schuur Hospital, University of Cape Town, South Africa
Address correspondence to Clive H. Wilder-Smith, MD, Nociception Research Group, Bubenbergplatz 11, CH-3011 Berne, Switzerland. Address e-mail to cws{at}ggp.ch No reprints will be available.
| Abstract |
|---|
|
|
|---|
IMPLICATIONS: The parenteral combination of tramadol and diclofenac resulted in more prolonged and pronounced postoperative analgesia and reduced sensory sensitization compared with the single drugs, with no increase in side effects.
| Introduction |
|---|
|
|
|---|
Postoperative neural sensitization is evident as hyperalgesia and allodynia, which can be demonstrated with quantitative sensory testing (811). Analgesic monotherapy has reduced, but not blocked, this sensitization, which is implicated in protracted pain (1014).
The aim of this placebo-controlled study was to assess the analgesic and antinociceptive effects of single doses of tramadol and diclofenac given alone and in combination in a homogeneous postoperative population. The influence of pharmacokinetic factors on analgesic effects was assessed by measuring tramadol and O-desmethyltramadol plasma levels and by phenotyping each patient for cytochrome P450 2D6 metabolizer status.
| Methods |
|---|
|
|
|---|
Patients were randomized before surgery to one of the four following treatment groups by using a computerized randomization list: 1) tramadol 100 mg (Tramal®; Grünenthal GmbH, Aachen, Germany) and placebo (0.9% NaCl), 2) sodium diclofenac 75 mg (Fortfen®; Compu Pharmaceutical Products, South Africa) and placebo, 3) tramadol 100 mg and sodium diclofenac 75 mg, or 4) placebo and placebo. The University Hospital Pharmacy performed blinding in identical and coded ampules.
Perioperative and anesthetic procedures were standardized. Patients received no premedication except prophylactic ampicillin 2 g IV, cimetidine 400 mg orally at 12 and 2 h before surgery, and sodium citrate 30 mg immediately before surgery. Spinal anesthesia was induced at L3-4 by using 0.5% bupivacaine with dextrose, dosed according to usual clinical standards (1.82 mL). The standardized IV fluid protocol was 20 mL/kg of modified lactated Ringers solution before the induction of spinal anesthesia; this continued at 1 L every 812 h for 24 h after surgery. No concomitant opioids were given. After surgery, the time of IM injection of the study drugs according to randomization was standardized to the time of regression of the sensory block to T10, which was tested by ethyl chloride swab beginning 1 h after surgery and repeated every 30 min, and patients with pain scores more than 2 on a five-point verbal rating scale (VRS; none, 0; mild, 1; moderate, 2; strong, 3; unbearable, 4) were included. The two study drug injections were given separately in the left and right buttock. Tramadol and diclofenac were not mixed because of the risk of incompatibility. All patients received prochlorperazine (Stemetil®) 12.5 mg IV for antiemetic prophylaxis.
On the basis of the usual departmental guidelines, morphine 10 mg IV was administered on demand up to every 4 h as analgesic rescue. No other analgesics were allowed in the first postoperative 24 h. The same two study personnel observed all patients.
Quantitative electrical sensory testing for sensation and pain tolerance thresholds was performed before and 4 and 24 h after surgery 1 cm from the incision for investigation of primary hyperalgesia and at a distant site, midclavicularly, for secondary hyperalgesia. A nerve stimulator (Digistim 3 Plus®; Organon Teknika, Switzerland) programmed to tetanic stimulation at 100 Hz and 0.2-ms square wave pulses and current increments of 1 mA/s was used. Subsequently, the phasic pain threshold was twice applied as a tonic suprathreshold stimulus for C-fiber activation for 60 s, and pain intensity was rated by VRS.
The cytochrome P450 2D6 metabolizer phenotype was determined with dextromethorphan 25 mg. Poor metabolizers were defined as having a dextromethorphan/dextrorphan metabolic ratio of >0.3 (15). Three postoperative blood samples were taken for population pharmacokinetics according to a randomized time schedule. Tramadol and the main metabolite, O-desmethyltramadol, were quantified by high-performance liquid chromatography.
All data were documented in standardized forms. The time to first analgesic demand after study drug injection was predefined as the primary efficacy variable. If no analgesic rescue was demanded within the maximum observation time of 24 h, a value of 1440 min was used as the time to first analgesic demand for statistical analysis. Secondary variables were pain at rest and during leg-raising and nausea intensity ratings (VRS: none, 0; mild, 1; moderate, 2; strong, 3; unbearable, 4) at 0, 30, 60, and 90 min and 2, 3, 4, 6, 7, 12, and 24 h after study drug injection, rescue drug use, and side effects.
Normally distributed, continuous data were analyzed by analysis of variance (ANOVA) and Tukeys honest significant difference tests. Nonparametric data were compared by using the Kruskal-Wallis ANOVA, followed by Mann-Whitney U-testing. A significance threshold of P < 0.05 was assumed. Power analysis based on preliminary pilot data revealed that a sample size of 27 patients per group was required to demonstrate a 20% difference in time to first analgesic rescue demand between the tramadol-alone and tramadol and diclofenac treatments.
The computer program NONMEM, Version 5 (NONMEM Project Group, University of California, San Francisco), was used for population pharmacokinetic analysis of tramadol and O-desmethyltramadol concentrations. Individual data from each group were pooled and plotted to generate a naïve population pharmacokinetic profile, on the basis of which it was decided to use a one-compartment approach to the analysis. A combined additive and exponential model was used to model intraindividual error. The predicted values for the resultant models for Groups 1 and 2 were then subjected to analysis with the Pharsight WinNonlin 1.5 Standard program to calculate the relevant pharmacokinetic variables.
| Results |
|---|
|
|
|---|
|
|
|
Median nausea ratings were 0 in all treatment groups at every time point throughout the 24-h period. Nausea was reported in four patients with tramadol and diclofenac (all slight intensity), in eight with tramadol and placebo (slight intensity, n = 5; moderate, n = 2; strong, n = 1), in six with diclofenac and placebo (slight, n = 5; unbearable, n = 1), and in five with double placebo (slight, n = 4; strong, n = 1). Vomiting occurred in six patients with tramadol and diclofenac, in three patients with tramadol and placebo, and in two patients each with diclofenac and placebo and double placebo. There were no significant group differences in the incidences of nausea and vomiting.
Sedation did not increase significantly from baseline during the 24-h study period, and median scores remained 0 in all groups throughout. Sleepiness or drowsiness in the first 24 postoperative hours was reported in 21 patients with tramadol and diclofenac, in 26 with tramadol and placebo, in 25 with diclofenac and placebo, and in 28 with double placebo. Respective incidences of dizziness and headache were n = 3 and 1, n = 11 and 3, n = 5 and 0, and n = 9 and 4. Incidences of shivering, cold, and hot were n = 0, 1, and 2 with tramadol and diclofenac; n = 1, 2, and 3 with tramadol and placebo; n = 1, 1, and 1 with diclofenac and placebo; and n = 2, 0, and 1 with double placebo, respectively. Miscellaneous other side effects were reported in five, two, six, and five patients, respectively. There were no serious side effects throughout the study. Overall, any side effects were reported in 16 patients with tramadol and diclofenac, in 21 patients with tramadol and placebo, in 20 patients with diclofenac and placebo, and in 18 patients with double placebo.
At incision, changes from baseline in sensation and pain tolerance thresholds were significantly greater with tramadol and diclofenac after 4 h, but not after 24 h, compared with tramadol and placebo and with double placebo (P < 0.05) (Fig. 3, A and B). Absolute sensation thresholds were higher after 4 h (P = 0.01) and pain tolerance thresholds were increased after 4 and 24 h compared with before surgery with tramadol and diclofenac (P < 0.01). With tramadol, diclofenac, or placebo alone, pain thresholds were significantly lower after 4 h than at baseline (P < 0.0002). Preoperative sensation thresholds and pain scores 2 h after surgery correlated inversely (r = -0.21; P = 0.03). Sensation thresholds over the wound correlated inversely with pain intensity after 4 h (r = -0.29; P = 0.003).
|
Preoperative sensation and pain thresholds correlated weakly but significantly inversely with pain scores 2 h after surgery (r = -0.22, P = 0.02 and r = -0.26, P = 0.006, respectively). Preoperative sensory thresholds correlated significantly with threshold changes after surgery (Table 2). Sensory thresholds and the time to first injection or analgesic rescue doses did not correlate significantly.
|
There were 114 extensive or rapid metabolizers and 6 poor metabolizers of cytochrome P450 2D6 (2 each with tramadol and diclofenac and with double placebo, and 1 each with tramadol or diclofenac alone). Because of the small numbers of poor metabolizers, no statistical comparison of variables with extensive metabolizers was performed. The median time to first rescue analgesic (interquartile range) was 528 min (299757 min) in extensive metabolizers and 367 min in the 2 poor metabolizers in the tramadol with diclofenac group. In the tramadol with placebo group, the respective times to first rescue analgesia were 81 min (49114 min) and 30 min (there was only one poor metabolizer). There appeared to be a trend to decreased duration of action of tramadol in poor metabolizers. Explorative analysis showed a tendency to increased pain intensities in poor metabolizers during leg-raising (ANOVA; P = 0.06) but no differences in side effects or quantitative sensory testing in the tramadol treatment groups.
The pharmacokinetics of tramadol and O-desmethyltramadol are shown in Table 3. There were no significant differences in any variables.
|
| Discussion |
|---|
|
|
|---|
Tramadol monotherapy was clearly less effective than in combination with diclofenac; in some variables, it was less effective than diclofenac alone and was similar to placebo. Previous studies have shown tramadol to be an effective postoperative analgesic (1,2,16,17). The single-dose design of this study is likely to have emphasized a delayed onset of action of the monoaminergic action of single-dose tramadol, which is suggested by the similar time to first rescue, but there was a very prolonged time to second rescue (well within the duration of action of tramadol) compared with placebo. A slower onset of action than morphine has been previously noted (18). In an orthopedic surgery study, the time to first rescue analgesia was 18.7 hours after parenteral tramadol 100 mg and 15.2 hours after parenteral ketorolac 30 mg, and analgesia was rated as excellent in a larger percentage of patients with tramadol (19). In a second similar study using the same comparator drugs and doses, analgesic effects were not significantly different between the drugs (20). Because all our patients were pregnant, changes in metabolism or analgesic pathways or sensitivities in pregnancy could also explain the less than expected analgesia with tramadol. Induction of the cytochrome P450 2D6 enzyme in pregnancy is an unlikely explanation, because more of the metabolite O-desmethyltramadol, to which most of the µ-opioid activity is attributed, will be formed, and metabolizer status ratios were within the nonpregnant normal range (6,21).
The additional analgesic effect achieved by the addition of diclofenac to tramadol is unlikely to be explained by pharmacokinetic interactions, because diclofenac is mainly metabolized by the cytochrome P450 2C9 pathway, which is not one of the main metabolic pathways for tramadol. Accordingly, population pharmacokinetics for tramadol and O-desmethyltramadol were similar whether tramadol was given alone or with diclofenac.
Five percent of the patients were poor metabolizers in the cytochrome P450 2D6 pathway. They showed a trend to decreased duration and intensity of analgesia with tramadol, which could be explained by the generally smaller concentrations of the main opioid metabolite (6). Cytochrome P450 2D6 poor metabolizers showed no differences in side effects compared with fast metabolizers. Endogenous nociceptive function appeared similar between extensive and poor metabolizers, because all sensory thresholds and ratings were similar before surgery.
Animal and human studies have shown the importance of 5-hydroxytryptamine and noradrenergic mechanisms in modulating central, spinal, afferent, and efferent analgesic pathways and have also shown a synergism with µ-opioid agonism (5). NSAIDs exert their analgesic action via several pathways, including prostaglandin modulation supraspinally and spinally. The additive analgesic effects of opioids and NSAIDs are well documented (22,23). This study provided evidence of the additive effects of a NSAID and a mixed monoaminergic and opioid drug. The combination of additive analgesic actions, therefore, is useful in reducing postoperative pain, as suggested in the concept of balanced analgesia proposed by Kehlet et al. (3) and Kehlet (4).
Tramadol with diclofenac was tolerated similarly well as diclofenac or tramadol alone, and no significant increases in side effects were seen compared with placebo dosing. Overall rates of gastrointestinal complaints were small. It should be noted that this study was powered to investigate analgesic and nociceptive effects, but not differences in side effects.
Surgery causes allodynia and hyperalgesia both at the incision and at distant sites (primary and secondary hyperalgesia) (812). In this study, quantitative electrical sensory testing was used to assess primary hyperalgesia, mainly attributed to peripheral sensitization, and secondary hyperalgesia, due to central sensitization (9). Primary, but not secondary, hyperalgesia or allodynia developed in the early postoperative hours when tramadol or diclofenac was given alone. When both drugs were given in combination, sensation and pain thresholds were significantly increased after surgery at the incision and distant sites.
Opioids can reduce postoperative sensitization, especially secondary hyperalgesia and allodynia, and can also increase pain thresholds in nonoperative settings (8,1214,2427). In a rodent postoperative incisional model, A-
fibers sensitized more extensively than C-fibers (28). Because A-
fibers are preferentially activated by phasic, lower-intensity stimulation and C-fibers by tonic, higher-intensity stimulation, we used both phasic threshold testing and chronic suprathreshold stimulation to investigate this issue in humans. As predicted, phasic, lower-intensity stimulation demonstrated more marked sensitization effects than tonic, higher-intensity stimulation.
Preoperative sensation and pain thresholds correlated closely and inversely with postoperative sensitization. This was valid both for the wound and the distant sites and for the phasic and suprathreshold protracted stimulation. This robust correlation in a large number of patients implies that individuals with higher preoperative sensory thresholds or lower pain ratings during suprathreshold stimulation sensitize more extensively after surgery. The determinants of individual baseline sensory thresholds and the response to analgesics and to various types of noxious stimulus are multifactorial, including genetic and environmental factors, and these determinants differentially govern multiple interactive components of the peripheral, spinal, and central sensory pathways (29,30). This has been demonstrated in rodents and also appears likely in humans (29,30). Differential responses of each of the physiologic variables are therefore not surprising and may explain the absence of a close relationship between psychophysical and clinical pain measures. The good correlation between preoperative electrical sensory thresholds and postoperative threshold changes implies usefulness in the prediction of which patients are prone to postoperative sensitization, but it requires further examination in different pain models.
In conclusion, the combination of tramadol and diclofenac is more effective for postoperative analgesia and prevention of sensitization than the two drugs given individually. Preoperative sensory testing may be useful in predicting postoperative sensitization.
| Acknowledgments |
|---|
We gratefully acknowledge the expert pharmacokinetic analysis and advice of Justin J. Wilkins, MSc, Grant M. Langdon, MSc, and Peter Smith, PhD, of the Division of Pharmacology, Department of Medicine, University of Cape Town, South Africa.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
V. Martinez, D. Fletcher, D. Bouhassira, D. I. Sessler, and M. Chauvin The Evolution of Primary Hyperalgesia in Orthopedic Surgery: Quantitative Sensory Testing and Clinical Evaluation Before and After Total Knee Arthroplasty Anesth. Analg., September 1, 2007; 105(3): 815 - 821. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|